Skip to main content
Premium Trial:

Request an Annual Quote

Gentel Licenses IP from PriTest for Use in Protein Arrays

NEW YORK (GenomeWeb News) – Gentel Biosciences said today that it has signed a licensing agreement with diagnostic firm PriTest that expands its intellectual property portfolio in the area of nitrocellulose coatings for protein microarrays.
 
Under the terms of the exclusive agreement, Gentel has licensed US Patent No. 6,861,251, “Translucent solid matrix assay device for microarray analysis,” which covers arrays with a translucent nitrocellulose surface.
 
Gentel said in a statement that nitrocellulose surface chemistry offers “unparalleled sensitivity and dynamic range for protein microarray applications.”
 
The company did not disclose the financial terms of the licensing agreement.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.